Global Bronchitis Drugs Market 2018-2022

気管支炎治療薬の世界市場:抗生剤、抗炎症薬、気管支拡張薬、粘液溶解薬

◆タイトル:Global Bronchitis Drugs Market 2018-2022
◆商品コード:IRTNTR23805
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年12月19日
◆ページ数:106
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥318,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、気管支炎治療薬の世界市場について調査・分析し、市場概要、市場環境、気管支炎治療薬市場規模、薬剤種類別(抗生剤、抗炎症薬、気管支拡張薬、粘液溶解薬)分析、用途別(急性気管支炎、慢性気管支炎)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・気管支炎治療薬の世界市場概要
・気管支炎治療薬の世界市場環境
・気管支炎治療薬の世界市場動向
・気管支炎治療薬の世界市場規模
・気管支炎治療薬の世界市場:業界構造分析
・気管支炎治療薬の世界市場:薬剤種類別(抗生剤、抗炎症薬、気管支拡張薬、粘液溶解薬)
・気管支炎治療薬の世界市場:用途別(急性気管支炎、慢性気管支炎)
・気管支炎治療薬の世界市場:地域別市場規模・分析
・気管支炎治療薬の北米市場規模・予測
・気管支炎治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・気管支炎治療薬のアジア太平洋市場規模・予測
・気管支炎治療薬の主要国分析
・気管支炎治療薬の世界市場:意思決定フレームワーク
・気管支炎治療薬の世界市場:成長要因、課題
・気管支炎治療薬の世界市場:競争環境
・気管支炎治療薬の世界市場:関連企業情報(ベンダー分析)

About this market
For bettering the public understanding of the disease, many government as well as non-government agencies are taking initiatives to improve public awareness of bronchitis. Many organizations suggest not to treat acute bronchitis with antibiotics, as such drugs are not indicated for diseases like acute bronchitis. Moreover, there are a few not-for-profit foundations on asthma and other respiratory illnesses, such as the Asthma Foundation, which offer support to patients. Asthma Foundation focuses on increasing the awareness of respiratory illnesses, funds research for better treatments, and provides education on best practices. Such initiatives for generating awareness of bronchitis among patients and physicians will result in better diagnosis of bronchitis and help in the global market’s growth. Technavio’s analysts have predicted that the bronchitis drugs market will register a CAGR of close to 4% by 2022.
Market Overview
Strong pipeline
Bronchitis treatment has a strong pipeline due to the extensive R&D in this field. Currently, the bronchitis treatment pipeline has around 6 trials in phase I, phase II, and phase III, in which 3 are in phase III. There are a few promising molecules in the pipeline for indications such as acute and chronic bronchitis.
High economics burden of bronchitis
Incomplete or inaccurate diagnosing of chronic bronchitis can have a substantial impact on healthcare costs, resulting in a higher economic burden for people with the disease.
For the detailed list of factors that will drive and challenge the growth of the bronchitis drugs market during the 2018-2022, view our report.
Competitive Landscape
The bronchitis drugs market is moderately fragmented with the presence of several bronchitis drug manufacturers. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Bronchitis pipeline
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: SEGMENTATION BY DRUG TYPE
• Antibiotics
• Anti-inflammatory drugs
• Bronchodilators
• Mucolytics
PART 09: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Comparison by application
• Acute bronchitis – Market size and forecast 2017-2022
• Chronic bronchitis – Market size and forecast 2017-2022
Market opportunity by application
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• EMEA – Market size and forecast 2017-2022
• Americas – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• High use of antibiotics for bronchitis treatment
• Use of off-label drugs for bronchitis
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• GlaxoSmithKline
• Novartis
• Sanofi
PART 17: APPENDIX
• List of abbreviations



Exhibit 01: Parent market
Exhibit 02: Global respiratory drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs for bronchitis 2017-2018
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global bronchitis drugs market – Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global bronchitis drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: LABAs with their respective time of onset of action and duration of action
Exhibit 20: Global bronchitis drugs market by application – Market share 2017-2022 (%)
Exhibit 21: Comparison by application
Exhibit 22: Acute bronchitis – Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Acute bronchitis – Year-over-year growth 2018-2022 (%)
Exhibit 24: US FDA-approved LABAs and LAMAs FDC
Exhibit 25: Chronic bronchitis – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Chronic bronchitis – Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by application
Exhibit 28: Customer landscape
Exhibit 29: Global bronchitis drugs market by geography – Market share 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 32: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 35: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in Americas
Exhibit 37: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 38: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Market opportunity
Exhibit 41: Late-stage pipeline drugs for bronchitis 2017-2018
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: AstraZeneca: An overview
Exhibit 48: AstraZeneca – Business segments
Exhibit 49: AstraZeneca – Organizational developments
Exhibit 50: AstraZeneca – Geographic focus
Exhibit 51: AstraZeneca – Key offerings
Exhibit 52: GlaxoSmithKline: An overview
Exhibit 53: GlaxoSmithKline – Business segments
Exhibit 54: GlaxoSmithKline – Organizational developments
Exhibit 55: GlaxoSmithKline – Geographic focus
Exhibit 56: GlaxoSmithKline – Segment focus
Exhibit 57: GlaxoSmithKline – Key offerings
Exhibit 58: Novartis: An overview
Exhibit 59: Novartis – Business segments
Exhibit 60: Novartis – Organizational developments
Exhibit 61: Novartis – Geographic focus
Exhibit 62: Novartis – Segment focus
Exhibit 63: Novartis – Key offerings
Exhibit 64: Sanofi: An overview
Exhibit 65: Sanofi – Business segments
Exhibit 66: Sanofi – Organizational developments
Exhibit 67: Sanofi – Geographic focus
Exhibit 68: Sanofi – Segment focus
Exhibit 69: Sanofi– Key offerings



【掲載企業】

AstraZeneca
GlaxoSmithKline
Novartis
Sanofi

★調査レポート[気管支炎治療薬の世界市場:抗生剤、抗炎症薬、気管支拡張薬、粘液溶解薬] (Global Bronchitis Drugs Market 2018-2022 / IRTNTR23805)販売に関する免責事項
[気管支炎治療薬の世界市場:抗生剤、抗炎症薬、気管支拡張薬、粘液溶解薬] (Global Bronchitis Drugs Market 2018-2022 / IRTNTR23805)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆